Related references
Note: Only part of the references are listed.Persistence and compliance of medications used in the treatment of osteoporosis - analysis using a large scale, representative, longitudinal German database
Volker Ziller et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2012)
Incidence of Atypical Nontraumatic Diaphyseal Fractures of the Femur
Richard M. Dell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Effectiveness of Teriparatide in Postmenopausal Women with Osteoporosis and Glucocorticoid Use: 3-Year Results from the EFOS Study
Dimitrios Karras et al.
JOURNAL OF RHEUMATOLOGY (2012)
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis
S. Lekamwasam et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial
M. Hakala et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2012)
Inflammatory Rheumatic Disorders and Bone
Irene E. M. Bultink et al.
CURRENT RHEUMATOLOGY REPORTS (2012)
Should Bisphosphonates Be Used for Long-Term Treatment of Glucocorticoid-Induced Osteoporosis?
Steven L. Teitelbaum et al.
ARTHRITIS AND RHEUMATISM (2011)
Clinical Question: What is the best approach to managing glucocorticoid-induced osteoporosis?
Juliet Compston
CLINICAL ENDOCRINOLOGY (2011)
Glucocorticoid-Induced Bone Disease
Robert S. Weinstein
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Oral bisphosphonate compliance and persistence: a matter of choice?
S. L. Silverman et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Adherence and profile of non-persistence in patients treated for osteoporosis-a large-scale, long-term retrospective study in The Netherlands
J. C. Netelenbos et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Advances in Glucocorticoid-Induced Osteoporosis
Debby den Uyl et al.
CURRENT RHEUMATOLOGY REPORTS (2011)
Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates
Robin K. Dore et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice
M. C. van der Goes et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
From bone biology to clinical outcome: state of the art and future perspectives
Georg Schett et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Silencing Dkk1 expression rescues dexamethasone-induced suppression of primary human osteoblast differentiation
Joseph S. Butler et al.
BMC MUSCULOSKELETAL DISORDERS (2010)
Regulation of Human Bone Marrow Stromal Cell Proliferation and Differentiation Capacity by Glucocorticoid Receptor and AP-1 Crosstalk
Ivan Carcamo-Orive et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research
Elizabeth Shane et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis
T. Beukelman et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Compliance and persistence with osteoporosis medications: A critical review of the literature
Stuart Silverman et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2010)
American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Jennifer M. Grossman et al.
ARTHRITIS CARE & RESEARCH (2010)
Effects of Teriparatide Versus Alendronate for Treating Glucocorticoid-Induced Osteoporosis Thirty-Six-Month Results of a Randomized, Double-Blind, Controlled Trial
Kenneth G. Saag et al.
ARTHRITIS AND RHEUMATISM (2009)
Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3β
Sun-Il Yun et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2009)
Ibandronate Prevents Bone Loss and Reduces Vertebral Fracture Risk in Male Cardiac Transplant Patients: A Randomized Double-Blind, Placebo-Controlled Trial
Astrid Fahrleitner-Pammer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial
S. Aubrey Stoch et al.
JOURNAL OF RHEUMATOLOGY (2009)
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
David M. Reid et al.
LANCET (2009)
Preferences of GPs and Patients for Preventive Osteoporosis Drug Treatment A Discrete-Choice Experiment
Esther W. de Bekker-Grob et al.
PHARMACOECONOMICS (2009)
How Antirheumatic Drugs Protect Joints From Damage in Rheumatoid Arthritis
Georg Schett et al.
ARTHRITIS AND RHEUMATISM (2008)
Modulation of dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss
Feng-Sheng Wang et al.
ENDOCRINOLOGY (2008)
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels
Takeshi Kondo et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
Teriparatide or alendronate in glucocorticoid-induced osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Relative value of 25(OH)D and 1,25(OH)2D measurements
Paul Lips
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
E. Canalis et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis
Benjamin M. P. Tang et al.
LANCET (2007)
Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids
T. P. van Staa et al.
RHEUMATOLOGY (2007)
Fracture risk with intermittent high-dose oral glucocorticoid therapy
Frank de Vries et al.
ARTHRITIS AND RHEUMATISM (2007)
Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year
E. D. Newman et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Glucocorticoids suppress bone formation via the osteoclast
Hyun-Ju Kim et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass
K Natsui et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club
JP Devogelaer et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Assessment of fracture risk
JA Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts
K Ohnaka et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids
TP van Staa et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2005)
Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength
CA O'Brien et al.
ENDOCRINOLOGY (2004)
Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k
Y Liu et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Glucocorticoids in the treatment of rheumatic diseases - An update on the mechanisms of action
F Buttgereit et al.
ARTHRITIS AND RHEUMATISM (2004)
A meta-analysis of prior corticosteroid use and fracture risk
JA Kanis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy
TP Van Staa et al.
ARTHRITIS AND RHEUMATISM (2003)
The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: A meta-regression
S Amin et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: Correlation with CCAAT-enhancer binding protein expression
RC Pereira et al.
BONE (2002)
Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice
B Gudbjornsson et al.
ANNALS OF THE RHEUMATIC DISEASES (2002)
The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis
TP van Staa et al.
OSTEOPOROSIS INTERNATIONAL (2002)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy
S Wallach et al.
CALCIFIED TISSUE INTERNATIONAL (2000)
Use of oral corticosteroids and risk of fractures
TP Van Staa et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial
DM Reid et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Use of oral corticosteroids in the United Kingdom
TP van Staa et al.
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS (2000)
Share Paper
